Kistler Tiffany Companies LLC grew its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 11.2% during the 3rd quarter, Holdings Channel reports. The fund owned 683 shares of the pharmaceutical company’s stock after acquiring an additional 69 shares during the period. Kistler Tiffany Companies LLC’s holdings in Vertex Pharmaceuticals were worth $116,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. Next Capital Management LLC lifted its position in shares of Vertex Pharmaceuticals by 84.4% in the second quarter. Next Capital Management LLC now owns 166 shares of the pharmaceutical company’s stock valued at $30,000 after acquiring an additional 76 shares in the last quarter. Evolution Wealth Advisors LLC purchased a new stake in shares of Vertex Pharmaceuticals in the second quarter valued at $32,000. Patriot Financial Group Insurance Agency LLC lifted its position in shares of Vertex Pharmaceuticals by 118.5% in the second quarter. Patriot Financial Group Insurance Agency LLC now owns 177 shares of the pharmaceutical company’s stock valued at $32,000 after acquiring an additional 96 shares in the last quarter. HM Payson & Co. purchased a new stake in shares of Vertex Pharmaceuticals in the second quarter valued at $35,000. Finally, Captrust Financial Advisors lifted its position in shares of Vertex Pharmaceuticals by 204.1% in the second quarter. Captrust Financial Advisors now owns 222 shares of the pharmaceutical company’s stock valued at $41,000 after acquiring an additional 149 shares in the last quarter. Institutional investors and hedge funds own 94.85% of the company’s stock.
In other news, EVP David Altshuler sold 12,501 shares of the stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $186.38, for a total value of $2,329,936.38. Following the completion of the sale, the executive vice president now owns 35,803 shares in the company, valued at $6,672,963.14. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Sangeeta N. Bhatia sold 8,379 shares of the stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $166.80, for a total value of $1,397,617.20. Following the completion of the sale, the director now owns 7,810 shares of the company’s stock, valued at approximately $1,302,708. The disclosure for this sale can be found here. Insiders have sold 39,803 shares of company stock valued at $7,157,258 over the last 90 days. 0.70% of the stock is currently owned by insiders.
NASDAQ VRTX opened at $176.23 on Monday. The business’s 50-day moving average price is $174.45 and its 200 day moving average price is $175.65. Vertex Pharmaceuticals Incorporated has a twelve month low of $151.80 and a twelve month high of $195.81. The company has a market capitalization of $45.68 billion, a PE ratio of 62.27, a price-to-earnings-growth ratio of 2.18 and a beta of 1.43. The company has a current ratio of 3.74, a quick ratio of 3.63 and a debt-to-equity ratio of 0.12.
Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Wednesday, July 31st. The pharmaceutical company reported $0.99 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.75 by $0.24. The company had revenue of $941.29 million during the quarter, compared to analyst estimates of $884.66 million. Vertex Pharmaceuticals had a return on equity of 21.73% and a net margin of 64.13%. The firm’s revenue was up 25.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.94 earnings per share. Equities analysts predict that Vertex Pharmaceuticals Incorporated will post 3.42 EPS for the current year.
Vertex Pharmaceuticals announced that its Board of Directors has authorized a share repurchase plan on Wednesday, July 31st that allows the company to buyback $500.00 million in shares. This buyback authorization allows the pharmaceutical company to reacquire up to 1.2% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s leadership believes its shares are undervalued.
Several analysts have recently issued reports on VRTX shares. Goldman Sachs Group upgraded Vertex Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price objective for the company from $226.00 to $254.00 in a research report on Tuesday, September 3rd. Bank of America started coverage on Vertex Pharmaceuticals in a research report on Wednesday, October 16th. They issued a “buy” rating and a $220.00 price objective on the stock. JPMorgan Chase & Co. restated a “buy” rating and issued a $212.00 price objective on shares of Vertex Pharmaceuticals in a research report on Thursday, August 1st. ValuEngine downgraded Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, September 10th. Finally, Morgan Stanley increased their target price on Vertex Pharmaceuticals from $215.00 to $240.00 and gave the stock an “overweight” rating in a research report on Friday, September 6th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and fifteen have assigned a buy rating to the company. Vertex Pharmaceuticals currently has an average rating of “Buy” and an average price target of $211.57.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.
Recommended Story: Terms to Better Understand Call Options
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.